Valorisation internationale du programme AcSé

Publications

2023

• Geoerger B, Paoletti X, Bautista F, Gatz SA, Marshall LV, André N, Berlanga P, Ducassou S, Pasqualini C, Casanova M, Zwaan CM, Nysom K, Rubino J, Goff DV, Archambaud B, Abbou S, Schleiermacher G, Dufour C, Blanc P, Hoog-Labouret N, Buzyn A, Vassal G., AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial, Nat Med. 2023 Dec; 29(12):2985-2987. doi: 10.1038/s41591-023-02580-5. PMID: 37857712
• Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L., Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas, Cancer Immunol Immunother. 2023 Aug;72(8):2649-2657. doi: 10.1007/s00262-023-03449-9. Epub 2023 Apr 17. PMID: 37067554
• Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C., Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. PMID: 37429302 Clinical Trial.
• Brugières L, Cozic N, Houot R, Rigaud C, Sibon D, Arfi-Rouche J, Bories P, Cottereau AS, Delmer A, Ducassou S, Garnier N, Lamant L, Leruste A, Millot F, Moalla S, Morschhauser F, Nolla M, Pagnier A, Reguerre Y, Renaud L, Schmitt A, Simonin M, Verschuur A, Hoog Labouret N, Mahier Ait Oukhatar C, Vassal G., Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial, Eur J Cancer. 2023 Sep;191:112984. doi: 10.1016/j.ejca.2023.112984. Epub 2023 Jul 17. PMID: 37549532
• Blay JY, Cropet C, Mansard S, Loriot Y, De La Fouchardière C, Haroche J, Topart D, Tougeron D, You B, Italiano A, Le Brun-Ly V, Ferrero JM, Penel N, Fabbro M, Troussard X, Malka D, Ray-Coquard I, Leboulleux S, Fléchon A, Maubec E, Charles J, Dalle S, Taieb S, Garcia GCTE, Mandache AM, Colignon N, Gavrel M, Nowak F, Hoog Labouret N, Mahier Aït Oukhatar C, Gomez-Roca C., Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma, ESMO Open. 2023 Nov 1;8(6):102038. doi: 10.1016/j.esmoop.2023.102038. Online ahead of print. PMID: 37922690
• Gatz SA, Harttrampf AC, Brard C, Bautista F, Andre N, Abbou S, Rubino J, Rondof W, Deloger M, Rübsam M, Marshall LV, Hubschmann D, Nebchi S, Aerts I, Thebaud E, De Carli E, Defachelles AS, Paoletti X, Godin R, Miah K, Mortimer PGS, Vassal G, Geoerger B. Clin, Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: Arm C of the AcSé-ESMART trial, Cancer Res. 2023 Dec 5. doi: 10.1158/1078-0432.CCR-23-2959. Online ahead of print. PMID: 38051741

2022

• Berlanga P et al. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies, Cancer Discov. 2022 May 2;12(5):1266-1281. doi: 10.1158/2159-8290.CD-21-1136. PMID: 35292802
• Véron M et al. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial, Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11. PMID: 36335780 Clinical Trial

2021

• Aparicio T et al. The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program, Target Oncol. 2021 May;16(3):381-388. doi: 10.1007/s11523-021-00811-8. Epub 2021 Apr 13.
• Bautista F et al. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSe ́-ESMART Trial. J Clin Oncol. 2021 Nov 10;39(32):3546-3560. doi: 10.1200/JCO.21.01152. Epub 2021 Aug 4.
• Morscher R J. et al. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSe ́- ESMART trial. Eur J Cancer. 2021 Nov;157:268-277. doi: 10.1016/j.ejca.2021.08.010. Epub 2021 Sep 17.
• Pasqualini C. et al. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSe ́-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. Eur J Cancer. 2021 Jun;150:53-62. doi: 10.1016/j.ejca.2021.03.032. Epub 2021 Apr 20.

2020

• Ortiz Cuaran S et al. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 2020 Dec 1;26(23):6242-6553 (Acsé Vemurafenib) 
• Mazières J et al. Vemurafenib in Non-small Cell Lung cancer Patients With V600 BRAF Mutations and Non-V600 Mutations. Ann Oncol. 2020 Feb;31(2):289-294 (AcSé Vemurafenib)

2019

• Moro-Sibilot D et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé Phase II Trial. Ann Oncol. 2019 Dec 1;30(12):1985-1991 (AcSé Crizotinib)
• Broudic-Guibert M et al. Persistent Response to Vemurafenib in Metastatic Ameloblastoma With BRAF Mutation: a Case Report. J Med Case Rep. 2019 Jul 25;13(1):245 (AcSé Vemurafenib)

2016

• Buzyn A. et al. Equal Access to Innovative Therapies and Precision Cancer Care. Nature Reviews Clinical Oncology 13, 385-393. doi : 10.1038/nrclinonc.2016 (programme Acsé)
• Soria JC et al. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. Journal of Thoracic Oncology, Vol. 11 No. 2: e21-e23. doi: 10.1016/j.jtho.2015.08.001) (Acsé Crizotinib)

Communications orales

2021

Blay J-Y, Penel et al.“High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: the French AcSé Pembrolizumab study from Unicancer”. ASCO 2021 (AcSé-Pembrolizumab) – Poster Discussion

2020

ESMO 2020

• Rousseau B et al. High Activity of Nivolumab in Patients With Pathogenic Exonucleasic Domain POLE (edPOLE) Mutated Mismatch Reair proficient (MMRp) Advanced Tumors (AcSé Nivolumab)
• Blay J-Y et al. High Clinical Benefit Rates of Pembrolizumab in Very Rare Sarcoma Histotypes: First Results of the AcSé Pembrolizumab Study (AcSé Pembrolizumab)

JDP 2020

• Veron M et al. AcSé Nivolumab: résultats préliminaires pour le carcinome basocellulaire avancé (AcSé Nivolumab)
• Toulemonde E et al. AcSé Nivolumab : résultats préliminaires pour le carcinome trichoblastique (AcSé Nivolumab)

2019

WCLC 2019

Ortiz-Cuaran S et al. Circulating tumor DNA analysis depicts potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant non-small cell lung cancer (AcSé Vemurafenib)

SIOP 2019

• Gatz SA et al. European Proof of Concept Therapeutic Stratification trial of   Molecular Anomalies in Relapsed or Refractory Tumors in children and adolescents (AcSé eSMART - “ARM D: Olaparib and Irinotecan”)
• Geoerger B et al. Pediatric Cancer Precision Medicine: MAPPYACTS and ESMART (invited oral presentation in plenary session). Annual Meeting of the International Society of Pediatric Oncology SIOP 2019, Lyon France (AcSé eSMART)

2018

ITCC 2018

European Pediatric Precision Medicine Program in Recurrent Tumors: From Molecular Profiling Trial Towards AcSé-eSMART Multiarm Proof-of-concept Study (AcSé eSMART)

WCLC 2018

• Moro-Sibilot D et al. Activity of crizotinib in c-MET or c-ROS1 positive (+) NSCLC: results of the AcSé phase II trial (AcSé Crizotinib)
• Mazières J et al. Vemurafenib in Patients Harboring V600 and Non-V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial (AcSé Vemurafenib)

ASCO 2018

Vassal G et al. Biomarker-Driven Access to Crizotinib in ALK, MET or ROS1 Positive (+) Malignancies in Adults and Children: the French National AcSé Program (AcSé Crizotinib)  

2017

AACR 2017

Geoerger B et al. European Pediatric Precision Medicine Program in Recurrent Tumors: First Results From MAPPYACTS Moleculer Profiling Trial Towards AcSe-ESMART Proof-of-concept Study (AcSé eSMART)

ITCC 2017

• B. Geoerger. “Clinical Sequencing Programs – What’s After Profiling? AcSé ESMART and Other Targeting Trials”. (AcSé eSMART)
• S. Ducassou. “Cell Cycle, Apoptosis and Metabolics – Enasidenib (AG-221) ITCC-057 – ESMART Arm I”.  (AcSé eSMART)
• L. Marshall. "Cancer Immunotherapy for Pediatric Malignancies: Where to go? Checkpoint Inhibitors Alone and Combinations: Nivolumab + Cyclophosphamide ITCC-057 – ESMART Arm G" (AcSé ESMART)
• P. Berlanga. "Signal Transduction: AZD2017 + Selumetinib ITCC-057 - ESMART Arm H (AcSé eSMART)

ASH 2017

• Troussard X et al. Vemurafenib in Advanced Patients With Hairy Cell Leukemia (HCL): Results of the AcSé Phase II Trial (AcSé Vemurafenib)

2016

ASCO 2016

• Vassal G et al. Crizotinib in Children and Adolescents With Advanced ROS1, MET or ALK‑rearranged Cancer: Result of the AcSé Phase II Trial (AcSé Crizotinib)

ESMO 2016

• Blay J.Y et al. Vemurafenib in Non-melanoma V600 and Non-V600 BRAF Mutated Cancers: First Results of the AcSé Trial (AcSé Vemurafenib)
• Maubec E. et al. Cutaneous Squamous Cell Carcinomas (cSCCs) Induced by Vemurafenib (V) in Non-melanoma Patients (AcSé Vemurafenib)

SIOP 2016

“Efficacy of Crizotinib in ALK+, MET+ or ROS1+ Advanced Pediatric Malignancies: Results of the AcSé Phase II Trial” (AcSé Crizotinib)

Communications écrites

2016

ASCO 2016

Blay J.Y et al. Biomarker‑driven Access to Vemurafenib in BRAF-positive Cancers: Second Study of the French National AcSé Programme (Acsé Vemurafenib)

WCLC 2016

Mazières J et al. Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of The AcSé Trial (Acsé Vemurafenib)

Posters

2021

ASCO 2021 :

• Leboulleux S et al. Benefits of Pembrolizumab in Progressive Radioactive Iodine Refractory Thyroid Cancer: Results of the AcSé Pembrolizumab Study From Unicancer (AcSé Pembrolizumab)
• Blay J.Y et al. High Clinical Activity of Pembrolizumab in Chordoma, Alveolar Soft Part Sarcoma (ASPS) and Other Rare Sarcoma Histotypes: the French AcSé Pembrolizumab Study From Unicancer (AcSé Pembrolizumab) 

ESMO 2021 :

Pouessel D et al. Nivolumab in Pretreated Metastatic Penile Squamous Cell Carcinoma: Results of the Penile Cohort From the French Acsé Prospective Program (AcSé Nivolumab)

2020

ASH 2020

Hoang-Xuan K et al. First Results of the AcSé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort (AcSé Pembrolizumab)

ASCO GU 2020

Albiges L et al. Nivolumab in Metastatic Non-clear Cell Renal Cell Carcinoma: First Results of the AcSe Prospective Study (AcSé Nivolumab)

ESMO 2020

Blay J.Y et al. High Clinical Benefit Rates of Pembrolizumab in Very Rare Sarcoma Histotypes: First Results of the AcSé Pembrolizumab Study (AcSé Pembrolizumab)

2019

ESMO 2019

• Tournigand C et al. High Level of Activity of Nivolumab anti-PD-1 Immunotherapy and Favorable Outcome in Metastatic/refractory MSI-H Non-colorectal Cancer: Results of the MSI Cohort from the French AcSé Program (AcSé Nivolumab)
• Ortiz-Cuaran S et al. Circulating Tumor DNA (ctDNA) Analysis Depicts Mechanisms of Resistance and Tumor Response to BRAF Inhibitors in BRAF-mutant Non-small Cell Lung Cancer (AcSé Vemurafenib)

ASCO 2019

Gatz SA et al. European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents (AcSé eSMART - “ARM D : Olaparib and Irinotecan”)

2018

ESMO IO 2018

Marabelle A et al. AcSé Immunotherapy Trials: Anti-PD-1 Therapy for Adult Patients With Selected Rare Cancer Types (AcSé Nivolumab / AcSé Pembrolizumab)

ESMO 2018

• Vassal G et al. Biomarker-driven Access to Crizotinib in ALK, MET or ROS1 Positive (+) Malignancies in Adults and Children: the French National AcSé Program (AcSé Crizotinib)
• Mazières J et al. Vemurafenib in patients harboring BRAF V600 mutation. Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial (AcSé Vemurafenib)

ASCO 2018

Aparicio T et al. The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: results from the AcSé-crizotinib program (AcSé Crizotinib)

2017

ASH 2017

Brugieres L et al. Crizotinib in Advanced ALK+Anplastic Large Cell Lymphoma in Children and Adults : Results of The AcSé Phase II Trial (AcSé Crizotinib)

Ateliers pédagogiques

2018

AACR 2018

From the Statistical Bench to Bedside: implementing Proper Designs in the eSMART Paediatric Combination Phase I/II Trials (AcSé-eSMART)